Welcome to our dedicated page for Petvivo Hldgs news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on Petvivo Hldgs stock.
PetVivo Holdings develops and commercializes veterinary medical devices and biomedical therapeutics for companion animals and equines through PetVivo Animal Health and PetVivo AI. Its recurring company updates center on Spryng with OsteoCushion Technology, a veterinarian-administered intra-articular injection for joint-related conditions including lameness and osteoarthritis, and PrecisePRP, an off-the-shelf platelet-rich plasma product for veterinary use.
News also covers regulatory acknowledgements, product availability, licensing and commercialization activity, PetVivo.ai and AgenticPet AI technology, fiscal results, conference presentations, and capital-market communications. The company describes a strategy of applying human therapies to animal health and protects its biomaterials, products, production processes and methods of use through patents and trade secrets.
PetVivo Holdings (OTCQX: PETV) announced that its human health subsidiary Cosmeta Corp. has changed its name to Somatrix Technologies, Inc., positioning it as a dedicated platform for developing innovative biomaterial technologies and potential therapeutic products for human health.
Somatrix is expected to focus on next‑generation biocompatible and functional biomaterials, including extracellular matrix-based materials, designed to support tissue and bone repair, regeneration, restructuring and targeted drug or biologic delivery. According to PetVivo, this expands its long-term strategy by separating human and veterinary activities between Somatrix and PetVivo Animal Health, while sharing intellectual property and scientific expertise where appropriate. Research programs at Somatrix remain at various stages and future products will be subject to additional development, testing and regulatory requirements.
PetVivo (OTCQX: PETV) reported fiscal Q1 2027 results for the quarter ended June 30, 2026 and outlined major strategic initiatives, including entering an agreement to acquire R&D partner PiezoBioMembrane (PBM), subject to customary closing conditions and related financing.
The PBM deal is intended to combine patented piezoelectric biomaterials with PetVivo’s technologies and supports a three‑stage R&D program, with Stage B largely completed and Stage C safety and efficacy work underway as PetVivo prepares to seek FDA clearance for human applications incorporating Spryng.
The company expanded beta deployment of its PetVivo.ai platform, reporting a 50%–90% reduction in veterinary customer acquisition costs to under $43 and AI diagnostic accuracy of about 97%, and plans a SaaS launch within months. PetVivo also advanced new canine and equine Spryng® studies and added sales managers for key U.S. regions.
Subsequent events included another peer‑reviewed Spryng study in Veterinary Record, participation in major veterinary conferences, filing a federal grant with PBM and the University of Connecticut for at least five technologies, and concluding its commercial partnership with VetStem.
PetVivo (OTCQX: PETV) will host a conference call on Friday, August 14, 2026 at 5:00 p.m. Eastern time to discuss financial results for its fiscal first quarter ended June 30, 2026. The company plans to release the results in a press release prior to the call.
Management will lead a presentation followed by a Q&A session. Investors can join via dial-in at +1 669 444 9171 using Meeting ID 85778580447 and Passcode 067744, or through a live and replay webcast accessible from the Investors section of PetVivo’s website.
PetVivo Holdings (OTCQX: PETV; OTCID: PETVW) entered into a Termination and Settlement Agreement with VetStem, effective July 24, 2026, ending their Exclusive License and Supply Agreement for the PrecisePRP® product line and resolving all related matters.
According to PetVivo, all prior financial obligations under the license have been fully satisfied, with mutual releases covering substantially all claims, subject to customary continuing obligations. PetVivo’s remaining fixed obligation is an aggregate $75,000, payable in two cash installments, plus a potential additional payment if an inventory reconciliation shows transferred inventory below agreed minimum quantities. The agreement provides for returning remaining PrecisePRP® inventory to VetStem and confirms VetStem’s existing warrant to purchase 250,000 PetVivo common shares remains in effect. PetVivo states this allows greater focus on its proprietary technologies, including SPRYNG® with OsteoCushion® Technology, and broader growth initiatives.
PetVivo Holdings (OTCQX: PETV) announced publication in Veterinary Record of a peer-reviewed, prospective proof-of-concept clinical study evaluating Spryng® with OsteoCushion® Technology in dogs with stifle osteoarthritis and suspected cranial cruciate disease. The 40 client-owned dogs received a single intra-articular injection of PetVivo’s collagen-elastin hydrogel microparticulate device and were followed for 84 days using serial clinical exams, the modified Glasgow Composite Pain Scale (mGCPS), clinician assessments, and owner-reported measures.
According to PetVivo, 55% of dogs achieved at least a 25% improvement in the primary endpoint mGCPS, and statistically significant improvements occurred across all additional subjective clinician- and owner-assessed outcomes. Investigators concluded the biomaterial demonstrated feasibility within the subjective parameters studied, while emphasizing that further trials using objective outcome measures are warranted. The study, funded by PetVivo and conducted by a multi-center team of board-certified specialists at leading U.S. referral hospitals, was independently peer-reviewed. PetVivo now has three peer-reviewed publications on Spryng®, which the company views as strengthening scientific evidence, veterinarian confidence, and long-term adoption of its proprietary intra-articular biomaterial platform.
PetVivo (OTCQX: PETV) reported fiscal 2026 Q4 operational and full-year financial results and scheduled a June 29, 2026 earnings call. Key highlights include Health Canada authorization of Spryng as a veterinary medical device in Canada, with commercialization expected near late July.
PetVivo advanced its PetVivo.ai SaaS veterinary platform, reporting beta clients cut customer acquisition costs by 50%–90% to under $43 and targeting 80%–90% gross margins. The company also announced an acquisition agreement for PiezoBioMembrane, adding patented piezoelectric biomaterial technologies, subject to customary closing conditions.
PetVivo Holdings (OTCQX: PETV) will report financial results for the year ended March 31, 2026, on Monday, June 29, 2026, after market close. A conference call and live webcast are scheduled for 5:00 p.m. CT (6:00 p.m. ET) the same day.
PetVivo Holdings (OTCQX: PETV) agreed to acquire PiezoBioMembrane, a developer of functional biomaterials and piezoelectric technologies, via a merger.
PBM shareholders will receive 3,000,000 PETV shares, partly subject to milestone-based retention. The deal adds PBM’s biomaterials, patents, know-how, and clinical and regulatory assets, supporting medical device and therapeutic development in animal and human health. Closing depends on due diligence, financing, and other customary conditions.
PetVivo Holdings (OTCQX: PETV) will host a virtual investor event, “What Veterinarians Are Seeing and How Access Is Expanding,” on Tuesday, June 16, 2026, at 1 p.m. ET.
The session will cover Spryng with OsteoCushion Technology, veterinary feedback, and expanded sales and distribution access.
Peer To Peer Network announced that partner Tier 1 AI signed PetVivo Holdings (OTCQX:PETV) as an enterprise client to deploy an investor-intelligence solution across PETV's digital ecosystem on April 29, 2026.
Under the agreement Tier 1 AI will install three tags, deliver up to 3,000 investor profiles per month, and run a three-month trial across PETV sites (petvivo.com, petvivo.ai, petvivoanimalhealth.com). This is Tier 1 AI's ninth deployment and PTOP's third enterprise customer.